Welcome to our dedicated page for Milestone Pharmaceuticals SEC filings (Ticker: MIST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Milestone Pharmaceuticals Inc. (MIST) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central to understanding how Milestone reports on its cardiovascular drug programs, financial position, and material corporate events.
For Milestone, current reports on Form 8-K are especially important. Recent 8-K filings describe key milestones such as U.S. Food and Drug Administration approval of CARDAMYST™ (etripamil) nasal spray for adult paroxysmal supraventricular tachycardia (PSVT), acceptance of the company’s response to a Complete Response Letter, new PDUFA target dates, equity offerings, amendments to royalty purchase agreements, and the filing or use of corporate presentations. These filings often incorporate press releases that discuss clinical data, regulatory status, and financing terms in more detail.
Investors can also use this page to locate periodic reports such as annual reports on Form 10-K and quarterly reports on Form 10-Q, which Milestone references in its news releases. Those documents typically include audited or reviewed financial statements, discussions of research and development and commercial expenses, and risk factor sections addressing uncertainties around regulatory approvals, clinical trials, capital resources, and market conditions.
In addition, Milestone’s capital-raising activities are documented through registration statements and related filings, along with 8-Ks that summarize underwriting agreements, warrant terms, and senior secured convertible notes. These materials explain how the company finances the development and commercialization of CARDAMYST and the broader etripamil program.
On Stock Titan, users can view these filings as they are made available from EDGAR and rely on AI-powered summaries to highlight the main points in lengthy documents, including 10-Ks, 10-Qs, and 8-Ks. The platform also makes it easier to identify items related to topics such as regulatory approvals, financing transactions, and updates on the PSVT and AFib-RVR programs, helping readers navigate Milestone’s disclosure record more efficiently.
Milestone Pharmaceuticals Chief Medical Officer David Bharucha reported new equity awards and related share sales. On December 12, 2025, he acquired 100,000 performance stock units (PSUs) that vested when the FDA granted a New Drug Application approval letter for Cardamyst (etripamil), and he also received an option for 100,000 common shares at an exercise price of $1.74, vesting in two equal installments in 2026. On December 15, 2025, he sold 58,007 common shares at a weighted average price of $2.32 under a sell-to-cover arrangement for taxes. On January 26, 2026, 20,100 restricted stock units were converted into common shares, followed by the sale of 12,245 shares at a weighted average price of $1.93, also to cover tax liabilities. After these transactions, he directly owned 113,181 common shares and 60,300 restricted stock units, with remaining RSUs vesting in annual installments through 2029.
Milestone Pharmaceuticals Inc. Chief Operating Officer Nelson Jeffrey Edward reported multiple equity award events tied to Cardamyst (etripamil). A 100,000-share performance stock unit award vested after FDA New Drug Application approval of Cardamyst, with each PSU delivering one common share. He also received an option for 100,000 common shares at $1.74 per share, vesting in two equal installments on June 12, 2026 and December 12, 2026, subject to continued service. On January 26, 2026, 20,100 restricted stock units converted into common shares, and 12,245 shares were sold at a weighted average price of $1.93 under a sell-to-cover arrangement to satisfy tax liabilities, following an earlier 58,007-share sell-to-cover sale at $2.32 on December 15, 2025.
Milestone Pharmaceuticals Chief Commercial Officer Muller Lorenz reported multiple equity compensation events tied to regulatory and service milestones. On December 12, 2025, a performance stock unit award for 100,000 common shares vested after the U.S. Food and Drug Administration issued a New Drug Application Approval Letter for Cardamyst (etripamil), and a separate employee stock option for 100,000 shares with a
On
Milestone Pharmaceuticals CFO & EVP of Corp. Development Amit Hasija reported multiple equity transactions. On December 12, 2025, he acquired 100,000 common shares from a performance stock unit award that vested when the FDA issued a New Drug Application approval letter for Cardamyst (etripamil), and received an option for 100,000 shares at an exercise price of
On December 15, 2025, he sold 58,007 common shares at a weighted average price of
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported equity awards tied to FDA approval and routine tax-related sales. On December 12, 2025, he acquired 280,000 performance stock units and a matching 280,000-share stock option at $1.74, vesting in two equal tranches in 2026 after Cardamyst (etripamil) received a New Drug Application approval letter.
He also reported sell-to-cover sales of 133,054 common shares at $2.32 on December 15, 2025 and 34,523 shares at $1.93 on January 26, 2026, executed solely to cover income tax liabilities upon PSU and RSU vesting. On January 26, 2026, 66,600 RSUs converted into common shares as part of a four-year vesting schedule, leaving him with 482,744 common shares and 199,800 RSUs directly beneficially owned.
Milestone Pharmaceuticals Inc. filed a current report describing that it has issued a press release announcing the availability of CARDAMYST (etripamil) nasal spray in the United States. The product is indicated for the management of paroxysmal supraventricular tachycardia, a type of rapid heart rhythm. The press release with additional details is included as Exhibit 99.1 and is incorporated by reference into the report.
Milestone Pharmaceuticals Inc. reported that it has closed a previously arranged royalty financing tied to its drug candidate etripamil. Under a Royalty Purchase Agreement originally signed in March 2023, funds managed by RTW Investments agreed to pay a purchase price of $75.0 million after U.S. Food and Drug Administration approval of etripamil, in exchange for a right to receive tiered quarterly royalties on annual net product sales of etripamil in the United States.
On January 12, 2026, the company completed this transaction and received the $75.0 million payment from certain funds managed by RTW in return for the royalty interest. Going forward, those RTW-managed funds are entitled to the specified tiered royalty stream on U.S. sales of etripamil, while Milestone retains the upfront cash proceeds from the sale.
Milestone Pharmaceuticals President and CEO Joseph Oliveto reported pre‑planned stock sales under a Rule 10b5-1 trading plan. On January 7, 2026, he sold 500 common shares at $2.25 per share, and on January 8, 2026, he sold an additional 43,000 common shares at $2.25 per share. After these transactions, he directly beneficially owned 303,721 common shares.
The filing notes that the trading plan was adopted on September 30, 2025, which means the sales were scheduled in advance. The reported per-share price on January 8 is a weighted average; the shares were sold in multiple trades at prices ranging from $2.25 to $2.265.
A holder of Milestone Pharmaceuticals (MIST) common stock has filed a notice of intent to sell 79,500 shares through broker Morgan Stanley Smith Barney LLC on or around January 8, 2026 on the NASDAQ. The filing lists an aggregate market value of $170,925.00 for this planned sale and notes that 85,169,344 common shares were outstanding.
The securities to be sold were acquired on November 16, 2018 by exercising stock options for cash. The notice also reports that over the past three months there was a separate 10b5-1 sale for Joseph Oliveto of 500 common shares, with gross proceeds of $1,125.00. By signing, the seller represents they are not aware of undisclosed material adverse information about the company’s operations.
A holder of MIST common stock filed a Form 144 notice to potentially sell 500 common shares through Morgan Stanley Smith Barney LLC on or about 01/07/2026 on NASDAQ. The planned sale has an aggregate market value of $1,025.00, compared with 85,169,000 common shares outstanding.
The 500 shares were acquired on 11/16/2018 from the issuer by exercising previously granted stock options and paying the purchase price in cash. By signing the notice, the person for whose account the securities may be sold represents that they do not know of any material adverse information about the issuer’s current or prospective operations that has not been publicly disclosed.